Wallaby’s Avenir Coil System for Hemorrhagic Stroke Treatment Launched in Japan

December 27, 2021—Wallaby Medical, a developer of medical device products for treating stroke, has partnered with Japan Lifeline Co., Ltd. (JLL) to commercialize Wallaby’s Avenir coil system in Japan. JLL is a publicly listed medical device manufacturer and distributor with 48 sales offices across Japan. Wallaby Medical is based in Laguna Hills, California, and Shanghai, China.

Wallaby’s Avenir device is used in the intravascular embolization of intracranial aneurysms and other neurovascular malformations, such as arteriovenous malformations and arteriovenous fistulas. It is also used for arterial and venous embolization of peripheral blood vessels.

According to the company, the Avenir coil system’s design features complex framing, ultrasoft finishing, and instant detachment. A reduced first loop diameter of coils is intended to minimize coil herniation during aneurysm introduction. The framing effect provides wall apposition and implant distribution to facilitate dense packing. The ultrasoft finishing coils and ultrafine primary wire enhance softness and conformability, allowing for optimal space-seeking capability for the deployed coils to realize higher packing density.

Michael Alper, Chief Executive Officer of Wallaby Medical, commented in the press release, “We are dedicated to improving stroke patient care, and this partnership enables us to cover the entire Japan market immediately. JLL’s exceptional reach and relationships mean Japanese physicians will now have the Avenir coil system as the go-to device to deliver the best possible outcome for their patients.”

Keisuke Suzuki, President and Chief Executive Officer of JLL, added, “We are very pleased to bring Wallaby Medical’s highly competitive products to the Japanese cerebrovascular treatment field and provide physicians with new treatment options. The Avenir coil system allows us to enter the cerebrovascular area and also meets the needs of physicians in the abdominal aortic treatment area, where we are already strong. We are confident that our collaboration with Wallaby Medical will be an important milestone in the development of our business.”

In September 2019, Wallaby Medical announced European CE Mark approval and United States FDA 510(k) clearance of the Avenir embolic coil system.